What National Pharmaceutical Pricing Authority does

National Pharmaceutical Pricing Authority (NPPA) is a statutory regulatory authority constituted by Government of India Resolution on 29 August 1997 and attached to the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers. It functions as the sole independent regulator for pharmaceutical pricing in India under the Essential Commodities Act, 1955 and the Drugs (Price Control) Order, 2013, fixing and revising ceiling prices for scheduled formulations and retail prices for new drugs.

NPPA operates three core digital and physical platforms: the Integrated Pharmaceutical Database Management System (IPDMS 2.0), which captures production, import, export, market share, and profitability data from manufacturers across bulk drugs and formulations; the Pharma Sahi Daam App/Portal, a consumer-facing tool for verifying ceiling prices and filing overcharging grievances; and the Price Monitoring and Research Units (PMRUs), field offices in 32 State/UTs that execute monitoring, public awareness, and enforcement. Ceiling prices have been issued for 928 scheduled formulations and retail prices for approximately 3,111 new drugs. Price regulation has been extended into medical devices (coronary stents, knee implants, anti-rabies immunoglobulin, IV fluids) and, in public-interest interventions under Para 19 of DPCO 2013, into 106 anti-diabetic and cardiovascular drugs and 42 anti-cancer drugs (the latter generating reported savings of up to 90%, or Rs. 984 crores per annum, across 526 brands).

NPPA does not generate commercial revenue. It is wholly funded through Government of India budget allocations and does not charge for regulatory services. Its "customers" in the functional sense are Indian citizens and patients (beneficiaries of price control), pharmaceutical manufacturers and distributors (regulated entities filing Form IV and pricing submissions through IPDMS 2.0), State Drug Controllers (enforcement network), and government health schemes such as Ayushman Bharat. Leadership comprises a Chairman, Member Secretary, and authority members drawn from CDSCO, the Department of Expenditure (Chief Adviser - Cost), and the Department of Economic Affairs (Economic Adviser).

Name

National Pharmaceutical Pricing Authority

Legal name

National Pharmaceutical Pricing Authority

Website

https://nppa.gov.in

Company type

Private

Founded year

1997

Operating status

Operating

Short description

National Pharmaceutical Pricing Authority is the sole statutory regulator of pharmaceutical and medical device pricing in India, operating under the Department of Pharmaceuticals to fix ceiling prices, monitor compliance, and serve citizens, manufacturers, and government health schemes via IPDMS 2.0 and a 32-State PMRU network.

Ownership category

akta.pro rank

Product category

Pharmaceutical Price Regulation

akta.pro primary industry

Drug Regulators (Human Pharmaceuticals) (HLAJADAA)

akta.pro secondary industry

Government Pricing & Compliance (Medicare/Medicaid/340B/AMP/Best Price) (HLAIAKAE)

Keywords

• Drug price regulation
• Pharmaceutical pricing
• Ceiling price fixation
• Medicine affordability
• Pharmaceutical policy

Headquarters

HQ city

New Delhi

HQ country

India

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Others

Distribution channels3 records

Marketing channels4 records

Core offering

National Pharmaceutical Pricing Authority (NPPA) is the statutory regulator for pharmaceutical pricing in India, constituted in 1997 under the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers. It fixes and revises ceiling prices for drugs notified under Schedule-I of the Drugs (Price Control) Order (DPCO) 2013, provides retail prices for new drugs, regulates prices of medical devices (coronary stents, knee implants), and operates digital platforms (IPDMS 2.0 and Pharma Sahi Daam) plus a 32-state PMRU network to monitor compliance, prevent overcharging, and ensure affordable access to essential medicines.

Product overview

NPPA operates as a regulatory body rather than a commercial product company. Its primary digital offerings include the Pharma Sahi Daam App/Portal for consumer price verification and grievance registration, the Integrated Public Database Management System (IPDMS) 2.0 for pharmaceutical data management, and a network of Price Monitoring and Research Units (PMRUs) across 32 states. These work together as part of the CAPPMS framework to regulate and monitor drug prices, ensure availability of affordable medicines, and handle public complaints.

Differentiator

Problem solved

Functional benefit

Brands

• Pharma Sahi Daam: A platform/app for information on medicine prices and registering public grievances.
• IPDMS 2.0
• PMRU

Products and services

• Pharma Sahi Daam App/Portal Mobile app and web portal that enables consumers to verify ceiling prices of scheduled medicines and register public grievances about overcharging by pharmaceutical companies or retailers. Built for Indian citizens seeking price transparency for essential and life-saving medicines.
• Integrated Pharmaceutical Database Management System (IPDMS) 2.0 Comprehensive digital platform for managing, regulating, and monitoring prices of pharmaceutical products and medical devices. Enables online information collection from pharmaceutical manufacturers and serves as a significant step towards enhancing transparency, efficiency, and accountability in the pharmaceutical and medical devices sector. Used by pharmaceutical manufacturers for compliance submissions.
• Price Monitoring and Research Units (PMRUs) State/UT-level field units for strengthening monitoring, public awareness, and enforcement of drug pricing regulations across India. Currently operational in 32 State/UTs as NPPA's decentralized enforcement and outreach arm.
• CAPPMS (Consumer Awareness, Price Monitoring and Public Grievance System) Integrated framework for consumer awareness on drug pricing, monitoring of pharmaceutical prices, and handling of public grievances. Operates through PMRUs across states and integrates with the Pharma Sahi Daam portal and IPDMS 2.0.

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Department of Pharmaceuticals (DoP), Ministry of Chemicals & Fertilizers, Government of IndiacoreOthersNPPA is an attached office of the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers. It implements the National Pharmaceutical Pricing Policy, 2012 and the Drugs (Price Control) Orders issued by DoP. Powers are delegated to NPPA for fixing and revising drug prices as per DPCO provisions.
• Drug Controller General of India (CDSCO), Ministry of Health and Family WelfarecoreStrategic or Co-development PartnerCollaboration with CDSCO for integrated data collection, regulation, and improved services. Dr. Rajeev Singh Raghuvanshi serves as Drugs Controller General of India and is a member of NPPA Authority.
• Price Monitoring and Research Units (PMRUs) in 32 State/UTscoreOthersPMRUs established at State/UT levels for strengthening, monitoring and public awareness on drug pricing. NPPA is expanding outside Delhi through these units.
• NIPERs (National Institutes of Pharmaceutical Education and Research)minorStrategic or Co-development PartnerNPPA seeks to synergize with NIPERs for integrated data collection and undertake concurrent research and studies to enable credible contribution to policy development.
• State Drug ControllerscoreStrategic or Co-development PartnerNPPA collaborates with State Drug Controllers for integrated data collection, regulation, and improved services to the people. State Drug Controllers are listed as related entities on NPPA website.
• Department of Expenditure, Ministry of FinancecoreOthersAnand Kumar Pal, Chief Adviser (ICoAS) from the Office of Chief Adviser (Cost), Department of Expenditure, serves as a member of NPPA Authority.
• Department of Economic Affairs, Ministry of FinancecoreOthersDr. Rose Mary K. Abraham, Economic Adviser from Department of Economic Affairs, serves as a member of NPPA Authority.
• Pharmaceutical ManufacturersminorOthersPharmaceutical manufacturers operating in India who submit pricing data through IPDMS 2.0 and comply with DPCO regulations. Estimated over 60,000 medicines sold by over 2,30,000 retail chemists in trade channel.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Others

• IQVIA: Global pharmaceutical data, analytics, and consulting provider. Comparable on the data-infrastructure layer NPPA relies on (IPDMS 2.0), but as an enabling technology vendor rather than a regulatory peer.

Broad incumbents

• US Food and Drug Administration (FDA): The US federal regulator for drugs, biologics, medical devices, and food. A broader incumbent in the same regulatory space; FDA also engages in pricing-adjacent work through Centers for Medicare & Medicaid Services, though its core mandate is safety and efficacy rather than price.
• Therapeutic Goods Administration (TGA, Australia): Australia's regulator for therapeutic goods including medicines and medical devices. Broader incumbent in the same regulatory family; pricing happens separately via the Pharmaceutical Benefits Scheme, so TGA is most comparable on the regulatory-side mandate.
• Centers for Medicare & Medicaid Services (CMS): US federal agency administering Medicare/Medicaid, including drug pricing programmes (e.g., Inflation Reduction Act negotiation). Comparable as the US government's primary payer-side pharmaceutical price regulator; operates at much larger scale but with analogous tools (ceiling pricing, negotiation, programme compliance).
• European Medicines Agency (EMA): EU-level medicines regulator coordinating drug approvals across member states. Larger, supranational incumbent with safety/efficacy focus but engages with HTA bodies on pricing and reimbursement evidence requirements.
• Medicines and Healthcare products Regulatory Agency (MHRA): UK's national regulator for medicines, medical devices, and blood components. Comparable as a national statutory medicines regulator; broader remit than NPPA but same federal-regulator archetype.

Direct peers

• NHS Business Services Authority (NHSBSA): UK Arm's Length Body that processes NHS prescription pricing, reimburses community pharmacies, and supports drug tariff management. Comparable to NPPA in operating the financial/reimbursement backbone of a public drug-pricing system.
• Central Drugs Standard Control Organisation (CDSCO): India's counterpart drug regulator under the Ministry of Health & Family Welfare; oversees drug safety, approvals, and clinical trials. Sister federal regulator to NPPA with overlapping data and stakeholder relationships, though focused on safety rather than pricing.
• Pharmaceutical Management Agency (PHARMAC): New Zealand's crown entity that decides which medicines are subsidised and negotiates/regulates their pricing. Closely comparable in combining price regulation, formulary decision-making, and direct public-health impact via affordability.
• Patented Medicine Prices Review Board (PMPRB): Canada's federal drug price regulator with a near-identical mandate: setting ceiling prices for patented medicines and protecting consumers from excessive pricing. Most directly comparable single-function drug price regulator to NPPA.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/watch?v=Dg-wL_9v11o
• Xx.com/nppa_india
• Facebookfacebook.com/india.nppa

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about National Pharmaceutical Pricing Authority